

Supplementary figure 1: Quantification of immunoblot signals is presented as the mean \pm SD. (*n* = 3). Representative image is shown in Figure 2(f).



Supplementary figure 2: (a) Immunoblot analysis of primary myotubes cultured in DM for 48 h after cells were transfected with siCont or siNox4. (b) Quantification of immunoblot signals is presented. **p < 0.01 (n = 3).



Supplementary figure 3: Quantification of immunoblot signals is presented as the mean \pm SD. (n = 3). Representative image is shown in Figures 3(b) and 3(f). (a), Nox4; (b), myosin heavy chain 3 (MHC); (c), myogenin. **p < 0.01, #p < 0.001 (n = 3).



Supplementary figure 4: Nox4 rescue slightly promotes myoblast fusion. (a) *Nox4*-KO primary myoblasts infected with mock or Ad-Nox4 virus (MOI 10) for 24 h were incubated in differentiation medium (DM) for 3 days, and then stained with antibody against MHC (green) and DAPI for nucleus (blue). Scale bar, 50 μ m. For the experiment in a, differentiation index (b) was calculated as the percentage of nuclei in MHC-positive cells in total nuclei (*n* = 3). (c) The percentage of nuclei in MHC-positive cells were determined. **p* < 0.05 (*n* = 3). ns, no significant difference.



Supplementary figure 5: Myomaker expression was suppressed in Nox4-KO mice. *Mymk* mRNA levels in TA muscles of WT and KO mice during regeneration after CTX injury (Figure 1(c)) was determined by RT-qPCR, using *36B4* for normalization. The following primers were used: *Mymk* 5'-ATCGCTACCAAGAGGCGTT-3' and 5'-CACAGCACAGACAAACCAGG-3'; *36B4*, 5'-AGATTCGGGATATGCTGTTGG-3' and 5'-AAAGCCTGGAAGAAGGAGGTC-3'. **p < 0.01 (n = 3).



Supplementary figure 6: Knockdown of *Nox4* has no effect on the mRNA expression of *Minion*, *N-Wasp*, and *Rac1*. After C2C12 cells were treated with either siCont or siNox4 for 24 h and incubated in DM for 3 days, the mRNA levels of *Minion* (a), *N-Wasp* (b), and *Rac1* (c) during differentiation were analyzed by RT-qPCR, using *36B4* for normalization (*n* = 3). The following primers were used: *Minion*, 5'-GGACCACTCCCAGAGGAAGGA-3' and 5'-GGACCGACGCCTGGACTAAC-3'; *N-Wasp*, 5'-AAGGATGGGAAACTATTGTGGGA-3' and 5'-GACGGCCCAAAAGGTCTGTAA-3'; *Rac1*, 5'-CAATGCGTTCCCTGGAGAGAGTACA-3' and 5'-ACGTCTGTTTGCGGGTAGGAGAGA-3'; *36B4*, 5'-AGATTCGGGATATGCTGTTGG-3' and 5'-AAGCCTGGAAGAAGGAGGTC-3'.



Supplementary figure 7: Quantification of immunoblot signals is presented as the mean \pm SD. (*n* = 3). Representative image is shown in Figure 4(c). (a), Nox4; (b), myomaker. **p* < 0.05, ***p* < 0.01, #*p* < 0.001 (*n* = 3).



Supplementary figure 8: GKT137831 inhibits myoblast fusion in C2C12 cells. (a) C2C12 cells pretreated with DMSO or GKT137831 (GKT) for 24 h were cultured in DM for 3 days and then stained with antibody against MHC (green) and DAPI for nucleus (blue). Scale bar, 50 μ m. For the experiment in a, (b) the differentiation index was calculated as the percentage of nuclei in MHC-positive cells to total nuclei (n = 3). (c) The fusion index was determined as the percentage of nuclei in MHC-positive myotubes (≥ 10 nuclei) to total nuclei in MHC-positive myotubes. *p < 0.05 (n = 3). ns, no significant difference.



Supplementary figure 9: Quantification of immunoblot signals is presented as the mean \pm SD. (n = 3). Representative image is shown in Figure 4(f). (a), Nox4; (b), myomaker. *p < 0.05, **p < 0.01 (n = 3).



Supplementary figure 10: Uncropped immunoblot image for myomaker in Figure 4(f) using primary antibody (Abcam 188300).